25 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Subject ComfortPrimary· 1 day (Day of procedure, No follow-up)
The Universal Pain Assessment Tool (UPAT) was used to assess each subject's comfort perception with each paddle (SOC and INV).
The UPAT ranges from 0 to 10, where 0 represents 'no pain' and 10 'worst pain possible'.
Group
Value
95% CI
INVESTIGATIONAL
2.6
2.3 – 2.6
STANDARD OF CARE
4.0
3.6 – 4.1
Breast Tissue CoverageSecondary· 1 Day (Day of procedure, No Follow-up)
An expert technologist evaluated the performance of the SOC and the INV paddles in 388 subjects.
For each participant, the technologist answered which paddle was better at pulling in more breast tissue during imaging between SOC and INV (all subjects were imaged with both paddles during the same session).
The technologist rated the paddles using a 5-point Likert scale, where -2 and -1 values mean that the SOC paddle performed better or slightly better, 0 means equal performance between paddles, and 2 and 1 mean that the INV performed better or slightly better than the SOC paddle.
Note that
Rate -2 or -1 (SOC better or slightly better than INV)
Group
Value
95% CI
All Enrolled Subjects
69
Rate 0 ( SOC equal INV)
Group
Value
95% CI
All Enrolled Subjects
162
Rate 2 or 1 ( INV better or slightly better than SOC)
Group
Value
95% CI
All Enrolled Subjects
157
Overall Determination of Image QualitySecondary· 1 day (Day of procedure, No Follow-up)
An expert radiologist reviewed, side by side, 3D images acquired with the INV and the SOC paddles in 420 subjects.
The radiologist rated the images using a 5-point Likert scale, where -2 and -1 values mean that the images acquired with the SOC paddle have better or slightly better quality, 0 means equal quality between the images, and 2 and 1 mean that the images acquired with the INV paddle have better or slightly better quality than the SOC paddle.
To determine overall clinical image quality or image acceptability, the radiologist considered whether the images reviewed have fair lesion vis
Rate -2 or -1 (SOC better or slightly better than INV)
Group
Value
95% CI
All Enrolled Subjects
27
Rate 0 (SOC equal INV)
Group
Value
95% CI
All Enrolled Subjects
330
Rate 2 or 1 (INV better or slightly better than SOC)
Group
Value
95% CI
All Enrolled Subjects
63
Sponsor's own description
The goal of this study is to evaluate patient comfort during compression with a standard flat mammographic paddle and an investigational curved paddle. This is a study that will be performed with x-ray imaging and will be used to determine if an overall reduction in pain can be appreciated in patients without loss in image quality as compared to the current standard mammogram. Another benefit of the curved paddle may be an increase of perceivable and measurable tissue capture.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06148038 — CBD for Breast Cancer Primary Tumors
· Phase 1
· recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
· Phase 2
· recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
· Phase 2
· recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer
· NA
· recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
· Phase 2
· recruiting
Other Hologic, Inc. trials
Trials by the same sponsor.
NCT06636539 — Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device
· NA
· recruiting
NCT05199701 — Prospective Case Collection Study for New Mammography Technologies
· NA
· recruiting
NCT04671329 — A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
· NA
· completed
NCT03497234 — Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
· NA
· withdrawn
NCT03456583 — Brevera™ Breast Biopsy System Data Collection Study
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hologic, Inc.
Last refreshed: 21 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03611543.